PUBLIC INVESTOR OVERVIEW

Making the Invisible Injury Visible.

A differentiated miRNA point-of-care platform for objective traumatic brain injury assessment - as brain health moves to the forefront across sport, Defence and healthcare.

Clinically studied biomarkers. Proprietary IP. Evidence across civilian, sport and Defence-relevant cohorts. MVP development underway.

5	4	7	MVP
Clinical studies	Peer-reviewed publications	Candidate miRNA biomarkers	Engineering underway

GLIADIAGNOSTICS
BRINGING BRAIN SCIENCE TOGETHER



From validated biomarker science
→ to an integrated handheld platform

Sydney, Australia

Investigational technology in development; not approved for commercial clinical use. Future applications and claims remain subject to analytical, clinical and regulatory validation. For information only - not an offer or solicitation to buy or sell securities.

Brain injury is moving from awareness to accountability

Australian sport and Defence are both intensifying focus on concussion, mTBI and long-term brain health.

69M+

Estimated TBIs worldwide each year[1]

SPORT

Concussion, CTE & player welfare under renewed national scrutiny

DEFENCE

ADF/DVA focus increasing on mTBI & repetitive blast exposure

FDA

Blood-based TBI regulatory precedent now established

THE CLINICAL GAP

Current assessment remains heavily clinical.

- Symptoms, signs and history remain central to concussion assessment.
- CT is essential for structural injury, but can be normal in uncomplicated mTBI/concussion.
- Remote, field and sideline settings may lack rapid access to objective biological information.

WHY NOW

Why this matters now

- Sport: concussion is now a governance and player-welfare issue, not just a sideline issue.
- Defence: mTBI and repetitive blast exposure are receiving growing policy and research attention.
- Regulatory: FDA-cleared blood-based TBI tests validate the category.

Sources: Dewan et al., J Neurosurg 2019; ABC Investigations, 29 Jun 2026; Australian Defence, 1 Apr 2026; Department of Veterans' Affairs, updated 24 Jun 2026; FDA K234143.

The GLIA platform

Designed to bring objective biological information closer to the point of care - with future longitudinal optionality.

TARGET COMMERCIAL ARCHITECTURE



Portable reader + disposable test cartridge

Fingerstick whole blood*

Target ~20 min*

SIMPLE BY DESIGN

01

Collect

Intended fingerstick whole-blood workflow.

02

Analyse

Proprietary multiplex miRNA analysis within the developing point-of-care platform.

03

Know

Objective biological output designed to complement clinical assessment.

DIFFERENTIATION

Multiplex miRNA biology

No pre-injury baseline intended

Beyond the acute snapshot*

*Target workflow. The platform is being developed first for objective TBI assessment; future prognosis and recovery-monitoring applications would require additional evidence and regulatory clearance. Integrated device and sample-matrix development are in progress.

Investigational technology in development; not approved for commercial clinical use. Future applications and claims remain subject to analytical, clinical and regulatory validation. For information only - not an offer or solicitation to buy or sell securities.

Evidence, IP and development traction

Clinical evidence and IP are established; current work is focused on point-of-care translation.

5
Completed clinical studies

4
Peer-reviewed publications

300+
Military samples in US DoD / I-TAB research

IP
Exclusive licensed biomarker IP + GLIA-owned platform IP

DEVELOPMENT STATUS

Biomarker programme: TRL 7

Integrated PoC platform: TRL 3

- MVP engineering and assay integration are underway.
- Analytical performance is being benchmarked against established laboratory reference methods.
- Sample-matrix translation is progressing toward the intended whole-blood workflow.

CREDIBILITY NETWORK

Clinical • Defence • Engineering

Alfred / Monash
CSIRO
ADF & US DoD
Genesys Electronics Design

Founder-led programme supported by clinical, commercialisation, IP and manufacturing advisors.

Organisation references describe research/development relationships and do not imply endorsement.

Biomarker evidence established → IP secured → partners established → building now

Three markets where brain health matters now

Healthcare is the regulatory beachhead; Defence and Sport provide strategic validation, visibility and future scale.

1 Healthcare

INITIAL REGULATORY BEACHHEAD

Emergency care • trauma • suspected mTBI

The clearest route to regulated clinical adoption and recurring test utilisation.

2 Defence

STRATEGIC VALIDATION & EXPANSION

Operational medicine • blast exposure • field assessment

Defence-supported evidence and engagement provide a strategic pathway to demanding point-of-care use cases.

3 Sport

VISIBILITY & FUTURE SCALE

Concussion • athlete health • future sideline use

A high-visibility setting for research, evidence generation and future sport-specific applications.

COMMERCIAL MODEL

Device sale or reagent rental | **Recurring disposable cartridges** | **Service / maintenance** | **Licensing & platform partnerships**

Recurring cartridge economics are expected to be the primary long-term revenue driver.

Why GLIA, why now

Differentiated biology, protected IP, high-value validation relationships and an active MVP programme converge at the next value inflection.

WHY GLIA NOW

1

Biomarker evidence

Five clinical studies and four publications support the biomarker programme.

2

Defensible position

Exclusive licensed biomarker IP plus GLIA-owned platform IP.

3

High-value validation network

Healthcare, Defence and engineering relationships already established.

4

Building now

Integrated MVP development and analytical translation are underway.

NEXT VALUE INFLECTION

MVP +

Regulatory Readiness

Near-term priorities:

- Integrated MVP and assay translation
- Analytical benchmarking against laboratory reference methods
- Progression toward the intended whole-blood workflow
- User needs, design controls and regulatory readiness
- FDA Pre-Submission preparation and engagement

Target 18–24 month outcomes

Functional MVP • analytical evidence • FDA feedback • validation / manufacturing roadmap

Built on US$250K private pre-seed and >US$1M historical non-dilutive support.

Investor & strategic partner enquiries: ed@gliadiagnostics.com

Investigational technology in development; not approved for commercial clinical use. Future applications and claims remain subject to analytical, clinical and regulatory validation. For information only - not an offer or solicitation to buy or sell securities.